BioWorld Today here continues its occasional listings of governmentagencies seeking industrial licensees to commercialize their biotech-related research and development inventions. The following 8 offerswere submitted this week by the National Institutes of Health, Officeof Technology Transfer (OTT), for publication in the FederalRegister.

To obtain licensing information, and copies of the pending U.S.patent applications listed below, contact OTT licensing specialistsindicated.

National Cancer Institute

Therapy for Autoimmune Disease

Suppression of major histocompatibility complex (MHC) class Imolecule expression, in order to treat rheumatoid arthritis, psoriasis,juvenile diabetes, etc. Invention provides for developingpharmaceutical compounds that prevent MHC expression, based onmethimazole, thioureas and their derivatives. These agents alsoinhibit organ graft rejection in humans.

Application: 08/480,525

Filed: 6/7/95

Inventors: D. S. Singer, et al.

Contact: Carol Lavrich, (301) 496-7735, ext. 287

Shielding Tissues, Organs From Oxygen Toxicity

Antioxidant mimetic compounds act inside the cell to protect againstdamage by ionizing radiation, reperfusion injury, adult respiratorydistress syndrome, inflammation, carcinogenesis, aging. Additionally,their long-term administration to animals induced weight reductionwithout harmful side effects.

Application: 08/473,960

Filed: 6/7/94

Inventors: J. B. Mitchell, et al.

Contact: Carol Lavrich, (301) 496-7735, ext. 287

Heparin-Blocking Peptides For Cancer Therapy

Proteolysis-resistant peptide analogs modulate tumor growth andangiogenesis by inhibiting heparin. They are basic fibroblast growthfactor antagonists, and activate transforming growth factor-b.Derived from the adhesive protein thrombospondin, they havebinding constants 10 to 100 times those of current inhibitors; aresuitable for pharmaceutical preparations.

U. S. Patent No. 5,357,041, issued 10/18/94

Application: 08/287,718.

Filed: 3/21/94

Inventor: D.D. Roberts, et al.

Contact: Carol Lavrich, (301) 496-7735, ext. 287

Internal Standard For Amino Acid Sequencing

A parathyroid-hormone-derived peptide containing two or moreunnatural amino acid residues, e.g., ornithine, norvaline, norleucine,can be sequenced simultaneously with unknown peptide or protein.Method determines repetitive yields, lags, N-terminal blockage,discrimination between blank cycles.

Application: 08/215,085

Filed: 2/6/95

Inventors: D. C. Parmelee, et al.

Contact: J. Peter Kim, (301) 496-7056, ext. 264

Butterfly-Wing Pigments As DNA Probes

Highly fluorescent DNA analogs resemble purine nucleotides, can besite-specifically incorporated into oligonucleotides for conventionalDNA synthesis. One such pteridine analog, resembling guanosine,has been developed for real-time assay of HIV integrase. Other usesinclude fluorescently labeling DNA probes and PCR primers,studying DNA-protein interactions.

Application: 08/451,641

Filed: 5/26/95

Inventors: M. E. Hawkins, et al.

Contact: Robert Benson, (301) 496-7056, ext. 287

National Institute of Arthritis & Infectious Diseases

Rotavirus Vaccine Against Diarrhea

Rotaviruses are main cause of severe diarrhea worldwide. Inventiondescribes generation of a cold-adapted virus, non-replicating atnormal human body temperature, so may stimulate immune responsewithout illness. Given to 26 adults in a limited clinical trial, it provedsafe, attenuated, able to induce a virus-specific immune response.

Application: 08/500,564

Filed: 7/11/95 (PCT priority date)

Inventors: Y. Hoshino, et al.

Contact: Robert Benson, (301) 496-7056, ext. 287

Live Influenza A Virus Vaccine Candidates

Temperature-sensitive attenuating mutations inserted by site-directedmutagenesis into cDNA copy of a viral gene. Resulting construct"can be transferred to each new variant of Influenza A virus as itappears in nature."

Application: 08/481,631

Filed: 6/7/95

Inventors: B. Murphy, et al.

Contact: Robert Benson, (301) 496-7056, ext. 287

National Institute of Neurological Diseases & Stroke

Diagnosing Alzheimer's in Living Patient

At present, Alzheimer's disease can be diagnosed with certainty onlyin post mortem brain tissue. Invention provides reliable, method ofdiagnosing Alzheimer's in vivo by measuring any two of fourlaboratory values: (1) a specific potassium channel; (2) effect ofpotassium channel blockers on intracellular calcium levels; (3)response to an intracellular calcium activator; (4) amount of Gprotein, cp20.

Application: DHHS Ref. No. E-092-93/2

Filed: 9/26/95

Inventor: D. L. Alkon

Contact: Stephen Finley, (301) 496-7735, ext. 215

_ Compiled by David N. Leff

(c) 1997 American Health Consultants. All rights reserved.